(Total Views: 837)
Posted On: 06/11/2021 9:26:52 AM
Post# of 72440
Per JFM:
Justfactsmam Member Level Friday, 06/11/21 08:17:56 AM
Re: None 0
Post #
362205
of 362207
There is a recurring content (narrative) that shows up here to construct another "Strawman"...to knock down.
This "Strawman" consists of irrelevant information, incorrect assumptions, character assassination of Leo ... ALWAYS repeating "past" dispelled lies (proven as such), and never including the very obviouspositive position of where Brilacidin and IPIX's opportunities are today...
Citing a share price spike, 7 years ago...in a speculative biotech development company...irrelevant to today...is meaningless. (This is especially so since at the time, with the concerted effort by and coordination by "short" hedge funds, Mako and complicit law firm coordinating there was a confirmed attempt to manufacture a "takedown" of IPIX (then CTIX) by anonymous short-sellers.)
If not for Leo fighting and proving ALL CLAIMS WERE LIES...(as noted in a determination by a NY Federal District Court that the allegations and cause of action were all bogus/lies)...Brilacidin would not be on the verge of becoming recognized as a potentially block-buster Covid-19 Therapeutic.
https://seekingalpha.com/article/3919626-trut...ellceutix!
(Court dismissed the bogus allegations and the case...which was based upon fabrications and lies of Short-Sellers and Mako...and as the subsequent article noted:
" While Mr. Ehrlich does a fine job representing, props must also be given to his legal team. Last year, the CTIX legal team sent a similar Mako attack to the recycle bin when a District Court judge published a scathing decision on its CTIX editorial, finding that the accusations had absolutely no merit whatsoever." )
The allegations in that action(dismissed) still constantly appear ...by the same cast of characters..."Leo is a Fraud" "Brilacidin has no efficacy" "the company is going bankrupt" etc, etc, etc... SOUND FAMILIAR?
https://cnafinance.com/cellceutix-ctix-gets-m...ites-next/
If content is to be be relevant ...current facts and accomplishment smust be cited (see below) and as in SP increase of the last 18 months... $.05 to $.22
ADD in... that IPIX is the crosshairs of approval of Covid-19 Therapruetic, Brilacidin...
IMO...upon Brilacidin/Covid-19 approval (or EUA) a realistic SP movement... in the next 18 months... $.22 to $22.00.
and that could be for Covid-19 and related viruses alone...
and without addressing the PR'd UC and OM clinical trials (pipeline: https://www.ipharminc.com/stages-of-development)
...and with Brilacidin NEVER HAVING A FAILING CLINICAL TRIAL!
https://www.ipharminc.com/stages-of-development
https://www.ipharminc.com/press-release
June 3, 2021
INNOVATION PHARMA COMPLETES ENROLLMENT IN PHASE 2 CLINICAL TRIAL FOR COVID-19
May 27, 2021
PATIENT ENROLLMENT REACHES 90 PERCENT IN INNOVATION PHARMA’S PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR COVID-19
May 13, 2021
INNOVATION PHARMA FILES FORM 10-Q; PATIENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR COVID-19 TOPS 70 PERCENT
April 28, 2021
INNOVATION PHARMA SURPASSES 50 PERCENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR COVID-19
April 14, 2021
INNOVATION PHARMA’S BROAD SPECTRUM ANTIVIRAL DRUG CANDIDATE BRILACIDIN HIGHLIGHTED IN BIODEFENSE AND INFECTIOUS DISEASES COVID-19 PRESENTATION
April 7, 2021
INNOVATION PHARMA ANNOUNCES BRILACIDIN ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT THE AMERICAN SOCIETY FOR VIROLOGY’S ANNUAL MEETING
April 5, 2021
INNOVATION PHARMA COMPLETES INTERIM SAFETY DATA REVIEW—DMC APPROVES INCREASED DOSING FREQUENCY IN PHASE 2 CLINICAL TRIAL OF BRILACIDIN IN HOSPITALIZED COVID-19 PATIENTS
March 10, 2021
INNOVATION PHARMA’S COVID-19 DRUG CANDIDATE BRILACIDIN RANKED IN TOP THREE PERCENT OF COMPOUNDS PREDICTED TO BE MOST EFFECTIVE AGAINST SARS-COV-2
March 5, 2021
RECRUITMENT AND ENROLLMENT UNDERWAY AT EIGHT SITES FOR INNOVATION PHARMA’S PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR COVID-19
March 2, 2021
INNOVATION PHARMACEUTICALS ANNOUNCES PUBLICATION OF PEER-REVIEWED SCIENTIFIC ARTICLE IN THE JOURNAL VIRUSES ON THE ANTI-SARS-COV-2 PROPERTIES OF BRILACIDIN
February 26, 2021
INNOVATION PHARMA PROVIDES STUDY DETAILS FOR ONGOING PHASE 2 CLINICAL TRIAL OF BRILACIDIN IN HOSPITALIZED COVID-19 PATIENTS
January 29, 2021
INNOVATION PHARMACEUTICALS’ PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR TREATING COVID-19 SCHEDULED TO BEGIN NEXT WEEK
January 14, 2021
INNOVATION PHARMACEUTICALS’ BRILACIDIN FOR THE TREATMENT OF COVID-19 RECEIVES FDA FAST TRACK DESIGNATION
December 21, 2020
FDA GRANTS IND APPROVAL FOR PHASE 2 CLINICAL TRIAL OF INNOVATION PHARMACEUTICALS’ BRILACIDIN FOR TREATING COVID-19
November 30, 2020
INNOVATION PHARMACEUTICALS COVID-19 CLINICAL TRIAL TO SUPPORT ADDITIONAL DEVELOPMENT OF BRILACIDIN AS A “PAN-CORONAVIRUS” THERAPEUTIC
November 16, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES OVERSEAS REGULATORY FILING SUBMITTED FOR COVID-19 CLINICAL STUDY
November 2, 2020
INNOVATION PHARMACEUTICALS RECEIVES PRE-IND RESPONSE FROM FDA ON COVID-19 TRIAL
October 30, 2020
INNOVATION PHARMACEUTICALS AND GEORGE MASON UNIVERSITY ANNOUNCE PUBLIC RELEASE OF LABORATORY TESTING RESULTS DEMONSTRATING BRILACIDIN’S COVID-19 TREATMENT POTENTIAL
October 2, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES PRE-IND MEETING REQUEST GRANTED BY FDA FOR THE STUDY OF BRILACIDIN FOR THE TREATMENT OF COVID-19
September 15, 2020
LABORATORY TESTING OF BRILACIDIN FOR COVID-19 IN COMBINATION WITH REMDESIVIR REDUCES VIRAL LOAD BY NEARLY 100 PERCENT
September 8, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES PUBLICATION OF INDEPENDENT RESEARCH ON KEVETRIN, THE COMPANY’S P53 DRUG CANDIDATE, IN ONCOLOGY REPORTS
August 26, 2020
DR. WILLIAM F. DEGRADO, A DISCOVERER OF BRILACIDIN, JOINS INNOVATION PHARMACEUTICALS AS SCIENTIFIC ADVISOR
August 24, 2020
COVID-19 DRUG CANDIDATE BRILACIDIN ACHIEVES A SELECTIVITY INDEX AMONG THE HIGHEST REPORTED, EXHIBITING POTENT ANTI-SARS-COV-2 ACTIVITY AT LOW CONCENTRATIONS; CLINICAL TRIAL FORTHCOMING
August 4, 2020
INNOVATION PHARMACEUTICALS AND U.S. REGIONAL BIOCONTAINMENT LABORATORY NEARING COMPLETION OF BRILACIDIN ANTI-SARS-COV-2 (COVID-19) IN VITRO TESTING
July 22, 2020
INNOVATION PHARMACEUTICALS GRANTS LICENSING RIGHTS TO FOX CHASE CHEMICAL DIVERSITY CENTER, INC. FOR ANTIFUNGAL TECHNOLOGY
July 20, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN INHIBITS NOVEL CORONAVIRUS (COVID-19) BY ALMOST 90% AT THE LOWEST CONCENTRATION TESTED TO DATE IN A HUMAN LUNG CELL LINE
July 13, 2020
INNOVATION PHARMACEUTICALS – CLINICAL TRIAL TESTING OF BRILACIDIN AGAINST SARS-COV-2 (COVID-19) TARGETED TO COMMENCE Q4 2020
July 7, 2020
IN VITRO TESTING OF INNOVATION PHARMACEUTICALS’ BRILACIDIN FOR COVID-19 SHOWS CONSISTENT ANTI-SARS-COV-2 EFFICACY; MANUFACTURING PREPARATION UNDERWAY FOR COVID-19 CLINICAL TRIAL
June 17, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN INHIBITS SARS-COV-2 (COVID-19) BY 97 PERCENT IN A HUMAN LUNG CELL LINE
June 11, 2020
INNOVATION PHARMACEUTICALS COLLABORATING WITH REGIONAL BIOCONTAINMENT LAB ON GRANT APPLICATION TO RESEARCH BRILACIDIN AS A PAN-CORONAVIRUS THERAPEUTIC
May 26, 2020
INNOVATION PHARMACEUTICALS RECEIVES DATA FROM PUBLIC HEALTH RESEARCH INSTITUTE SHOWING BRILACIDIN INHIBITS SARS-COV-2 (COVID-19) IN A HUMAN CELL LINE
May 19, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN REDUCES VIRAL TITER OF SARS-COV-2 (COVID-19) BY 75 PERCENT AFTER ONLY 1 HOUR OF PREINCUBATION IN IN VITRO STUDY AT BSL-3 FACILITY
May 5, 2020
INHIBITORY EFFECT OF INNOVATION PHARMACEUTICALS’ BRILACIDIN ON SARS-COV-2 (COVID-19) IN PRIMARY HUMAN IMMUNE CELLS TO BE STUDIED AT LEADING PUBLIC HEALTH RESEARCH INSTITUTE
April 27, 2020
INNOVATION PHARMACEUTICALS INFORMED NEXT PHASE OF BRILACIDIN CORONAVIRUS (COVID-19) TESTING TO BEGIN WEEK OF MAY 4
April 20, 2020
SCREENING OF 11,552 COMPOUNDS IDENTIFIES INNOVATION PHARMACEUTICALS’ BRILACIDIN AS ONE OF THE MOST PROMISING POTENTIAL INHIBITORS OF THE NOVEL CORONAVIRUS
April 6, 2020
INNOVATION PHARMACEUTICALS IN DISCUSSIONS TO ADVANCE BRILACIDIN INTO HUMAN TRIALS AGAINST COVID-19
April 1, 2020
INNOVATION PHARMACEUTICALS RECEIVES DATA SUPPORTING BRILACIDIN’S DIRECT INHIBITION OF SARS-COV-2, THE NOVEL CORONAVIRUS RESPONSIBLE FOR COVID-19
March 17, 2020
INNOVATION PHARMACEUTICALS BRILACIDIN TO BE RESEARCHED AS POSSIBLE NOVEL CORONAVIRUS (COVID-19) VACCINE; BRILACIDIN NOW BEING TESTED AS DRUG AND VACCINE AT DIFFERENT INSTITUTIONS
March 12, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES TESTING PROCEDURES OF BRILACIDIN AGAINST CORONAVIRUS (COVID-19)
March 10, 2020
U.S. REGIONAL BIOCONTAINMENT LAB TO BEGIN TESTING OF BRILACIDIN AGAINST CORONAVIRUS (COVID-19) NEXT WEEK
March 9, 2020
INNOVATION PHARMACEUTICALS BRILACIDIN RECEIVED BY U.S. REGIONAL BIOCONTAINMENT LABORATORY; TESTING AGAINST CORONAVIRUS (COVID-19)
March 6, 2020
INNOVATION PHARMACEUTICALS SIGNS SECOND MTA TO EXPLORE BRILACIDIN AS CORONAVIRUS COVID-19 TREATMENT
March 5, 2020
INNOVATION PHARMACEUTICALS PLANS FOR PHASE 2 TRIAL OF NEW TREATMENT FOR ULCERATIVE COLITIS
March 2, 2020
INNOVATION PHARMACEUTICALS PROVIDES SCIENTIFIC RATIONALE AND CLINICAL DEVELOPMENT PERSPECTIVES FOR BRILACIDIN AS A POTENTIAL NOVEL CORONAVIRUS COVID-19 TREATMENT
February 27, 2020
INNOVATION PHARMACEUTICALS TO SHIP BRILACIDIN TO U.S. REGIONAL BIOCONTAINMENT LABORATORY FOR RESEARCH AGAINST CORONAVIRUS COVID-19
February 24, 2020
INNOVATION PHARMACEUTICALS SUBMITS MATERIAL TRANSFER AGREEMENT TO STUDY LEAD DEFENSIN MIMETIC BRILACIDIN FOR CORONAVIRUS (COVID-19)
February 18, 2020
INNOVATION PHARMACEUTICALS EXPLORING LEAD DEFENSIN MIMETIC DRUG CANDIDATE BRILACIDIN AS POTENTIAL NOVEL CORONAVIRUS TREATMENT
February 13, 2020
INNOVATION PHARMACEUTICALS PHASE 1 TRIAL OF BRILACIDIN FOR ULCERATIVE COLITIS MEETS PRIMARY ENDPOINTS; POSITIVE TOPLINE RESULTS OF ORAL BRILACIDIN
January 29, 2020
INNOVATION PHARMACEUTICALS FURTHER ENGAGES LOCUST WALK TO LEAD OUT-LICENSING NEGOTIATIONS FOR RIGHTS TO PHASE 3-READY ORAL MUCOSITIS DRUG CANDIDATE
January 24, 2020
INNOVATION PHARMACEUTICALS COMPLETES DOSING IN PHASE 1 TRIAL FOR NEW ORAL ULCERATIVE COLITIS DRUG
January 17, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES DOSE ESCALATION
January 16, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES DOSING OF FIRST COHORT IN PHASE 1 TRIAL OF ORAL BRILACIDIN IN ULCERATIVE COLITIS PROGRAM; TOPLINE RESULTS ANTICIPATED EARLY Q1 2020
December 26, 2019
INNOVATION PHARMACEUTICALS: PATIENT SCREENING FOR PHASE 1 TRIAL OF ORAL BRILACIDIN IN ULCERATIVE COLITIS PROGRAM ON TRACK FOR EARLY JANUARY
December 13, 2019
INNOVATION PHARMACEUTICALS GRANTED REGULATORY APPROVAL TO START PHASE 1 TRIAL OF ORAL BRILACIDIN IN ULCERATIVE COLITIS PROGRAM
December 10, 2019
INNOVATION PHARMACEUTICALS PROVIDES UPDATE ON CLINICAL TRIALS AND REVENUE POTENTIAL OF BRILACIDIN IN INFLAMMATORY BOWEL DISEASES
November 25, 2019
INNOVATION PHARMACEUTICALS AND FDA AGREE TO WAIVE INITIAL PEDIATRIC STUDY PLAN REQUIREMENT REGARDING BRILACIDIN FOR THE PREVENTION OF ORAL MUCOSITIS
November 13, 2019
INNOVATION PHARMACEUTICALS: ORAL CANCER ON THE RISE; COMPANY OFFERS PERSPECTIVES ON OPPORTUNITY OF BRILACIDIN FOR THE PREVENTION OF ORAL MUCOSITIS
October 28, 2019
INNOVATION PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA BY INDEPENDENT CANCER RESEARCHERS SUPPORTING P53 DRUG CANDIDATE KEVETRIN’S POTENTIAL IN TREATING ACUTE MYELOID LEUKEMIA
October 14, 2019
INNOVATION PHARMACEUTICALS PARTNERING PROVIDES MOMENTUM FOR INFLAMMATORY BOWEL DISEASE PROGRAMS, TARGETING A SUBSTANTIAL AND PRIZED MARKET WITH A LARGE UNMET PATIENT NEED
October 8, 2019
INNOVATION PHARMACEUTICALS CITES RECENT ACADEMIC LITERATURE SHOWING HOST DEFENSE PROTEINS AT CUTTING-EDGE OF MEDICINE FOR MULTIPLE DISEASES
Justfactsmam Member Level Friday, 06/11/21 08:17:56 AM
Re: None 0
Post #
362205
of 362207
There is a recurring content (narrative) that shows up here to construct another "Strawman"...to knock down.
This "Strawman" consists of irrelevant information, incorrect assumptions, character assassination of Leo ... ALWAYS repeating "past" dispelled lies (proven as such), and never including the very obviouspositive position of where Brilacidin and IPIX's opportunities are today...
Citing a share price spike, 7 years ago...in a speculative biotech development company...irrelevant to today...is meaningless. (This is especially so since at the time, with the concerted effort by and coordination by "short" hedge funds, Mako and complicit law firm coordinating there was a confirmed attempt to manufacture a "takedown" of IPIX (then CTIX) by anonymous short-sellers.)
If not for Leo fighting and proving ALL CLAIMS WERE LIES...(as noted in a determination by a NY Federal District Court that the allegations and cause of action were all bogus/lies)...Brilacidin would not be on the verge of becoming recognized as a potentially block-buster Covid-19 Therapeutic.
https://seekingalpha.com/article/3919626-trut...ellceutix!
(Court dismissed the bogus allegations and the case...which was based upon fabrications and lies of Short-Sellers and Mako...and as the subsequent article noted:
" While Mr. Ehrlich does a fine job representing, props must also be given to his legal team. Last year, the CTIX legal team sent a similar Mako attack to the recycle bin when a District Court judge published a scathing decision on its CTIX editorial, finding that the accusations had absolutely no merit whatsoever." )
The allegations in that action(dismissed) still constantly appear ...by the same cast of characters..."Leo is a Fraud" "Brilacidin has no efficacy" "the company is going bankrupt" etc, etc, etc... SOUND FAMILIAR?
https://cnafinance.com/cellceutix-ctix-gets-m...ites-next/
If content is to be be relevant ...current facts and accomplishment smust be cited (see below) and as in SP increase of the last 18 months... $.05 to $.22
ADD in... that IPIX is the crosshairs of approval of Covid-19 Therapruetic, Brilacidin...
IMO...upon Brilacidin/Covid-19 approval (or EUA) a realistic SP movement... in the next 18 months... $.22 to $22.00.
and that could be for Covid-19 and related viruses alone...
and without addressing the PR'd UC and OM clinical trials (pipeline: https://www.ipharminc.com/stages-of-development)
...and with Brilacidin NEVER HAVING A FAILING CLINICAL TRIAL!
https://www.ipharminc.com/stages-of-development
https://www.ipharminc.com/press-release
June 3, 2021
INNOVATION PHARMA COMPLETES ENROLLMENT IN PHASE 2 CLINICAL TRIAL FOR COVID-19
May 27, 2021
PATIENT ENROLLMENT REACHES 90 PERCENT IN INNOVATION PHARMA’S PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR COVID-19
May 13, 2021
INNOVATION PHARMA FILES FORM 10-Q; PATIENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR COVID-19 TOPS 70 PERCENT
April 28, 2021
INNOVATION PHARMA SURPASSES 50 PERCENT ENROLLMENT IN PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR COVID-19
April 14, 2021
INNOVATION PHARMA’S BROAD SPECTRUM ANTIVIRAL DRUG CANDIDATE BRILACIDIN HIGHLIGHTED IN BIODEFENSE AND INFECTIOUS DISEASES COVID-19 PRESENTATION
April 7, 2021
INNOVATION PHARMA ANNOUNCES BRILACIDIN ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT THE AMERICAN SOCIETY FOR VIROLOGY’S ANNUAL MEETING
April 5, 2021
INNOVATION PHARMA COMPLETES INTERIM SAFETY DATA REVIEW—DMC APPROVES INCREASED DOSING FREQUENCY IN PHASE 2 CLINICAL TRIAL OF BRILACIDIN IN HOSPITALIZED COVID-19 PATIENTS
March 10, 2021
INNOVATION PHARMA’S COVID-19 DRUG CANDIDATE BRILACIDIN RANKED IN TOP THREE PERCENT OF COMPOUNDS PREDICTED TO BE MOST EFFECTIVE AGAINST SARS-COV-2
March 5, 2021
RECRUITMENT AND ENROLLMENT UNDERWAY AT EIGHT SITES FOR INNOVATION PHARMA’S PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR COVID-19
March 2, 2021
INNOVATION PHARMACEUTICALS ANNOUNCES PUBLICATION OF PEER-REVIEWED SCIENTIFIC ARTICLE IN THE JOURNAL VIRUSES ON THE ANTI-SARS-COV-2 PROPERTIES OF BRILACIDIN
February 26, 2021
INNOVATION PHARMA PROVIDES STUDY DETAILS FOR ONGOING PHASE 2 CLINICAL TRIAL OF BRILACIDIN IN HOSPITALIZED COVID-19 PATIENTS
January 29, 2021
INNOVATION PHARMACEUTICALS’ PHASE 2 CLINICAL TRIAL OF BRILACIDIN FOR TREATING COVID-19 SCHEDULED TO BEGIN NEXT WEEK
January 14, 2021
INNOVATION PHARMACEUTICALS’ BRILACIDIN FOR THE TREATMENT OF COVID-19 RECEIVES FDA FAST TRACK DESIGNATION
December 21, 2020
FDA GRANTS IND APPROVAL FOR PHASE 2 CLINICAL TRIAL OF INNOVATION PHARMACEUTICALS’ BRILACIDIN FOR TREATING COVID-19
November 30, 2020
INNOVATION PHARMACEUTICALS COVID-19 CLINICAL TRIAL TO SUPPORT ADDITIONAL DEVELOPMENT OF BRILACIDIN AS A “PAN-CORONAVIRUS” THERAPEUTIC
November 16, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES OVERSEAS REGULATORY FILING SUBMITTED FOR COVID-19 CLINICAL STUDY
November 2, 2020
INNOVATION PHARMACEUTICALS RECEIVES PRE-IND RESPONSE FROM FDA ON COVID-19 TRIAL
October 30, 2020
INNOVATION PHARMACEUTICALS AND GEORGE MASON UNIVERSITY ANNOUNCE PUBLIC RELEASE OF LABORATORY TESTING RESULTS DEMONSTRATING BRILACIDIN’S COVID-19 TREATMENT POTENTIAL
October 2, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES PRE-IND MEETING REQUEST GRANTED BY FDA FOR THE STUDY OF BRILACIDIN FOR THE TREATMENT OF COVID-19
September 15, 2020
LABORATORY TESTING OF BRILACIDIN FOR COVID-19 IN COMBINATION WITH REMDESIVIR REDUCES VIRAL LOAD BY NEARLY 100 PERCENT
September 8, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES PUBLICATION OF INDEPENDENT RESEARCH ON KEVETRIN, THE COMPANY’S P53 DRUG CANDIDATE, IN ONCOLOGY REPORTS
August 26, 2020
DR. WILLIAM F. DEGRADO, A DISCOVERER OF BRILACIDIN, JOINS INNOVATION PHARMACEUTICALS AS SCIENTIFIC ADVISOR
August 24, 2020
COVID-19 DRUG CANDIDATE BRILACIDIN ACHIEVES A SELECTIVITY INDEX AMONG THE HIGHEST REPORTED, EXHIBITING POTENT ANTI-SARS-COV-2 ACTIVITY AT LOW CONCENTRATIONS; CLINICAL TRIAL FORTHCOMING
August 4, 2020
INNOVATION PHARMACEUTICALS AND U.S. REGIONAL BIOCONTAINMENT LABORATORY NEARING COMPLETION OF BRILACIDIN ANTI-SARS-COV-2 (COVID-19) IN VITRO TESTING
July 22, 2020
INNOVATION PHARMACEUTICALS GRANTS LICENSING RIGHTS TO FOX CHASE CHEMICAL DIVERSITY CENTER, INC. FOR ANTIFUNGAL TECHNOLOGY
July 20, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN INHIBITS NOVEL CORONAVIRUS (COVID-19) BY ALMOST 90% AT THE LOWEST CONCENTRATION TESTED TO DATE IN A HUMAN LUNG CELL LINE
July 13, 2020
INNOVATION PHARMACEUTICALS – CLINICAL TRIAL TESTING OF BRILACIDIN AGAINST SARS-COV-2 (COVID-19) TARGETED TO COMMENCE Q4 2020
July 7, 2020
IN VITRO TESTING OF INNOVATION PHARMACEUTICALS’ BRILACIDIN FOR COVID-19 SHOWS CONSISTENT ANTI-SARS-COV-2 EFFICACY; MANUFACTURING PREPARATION UNDERWAY FOR COVID-19 CLINICAL TRIAL
June 17, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN INHIBITS SARS-COV-2 (COVID-19) BY 97 PERCENT IN A HUMAN LUNG CELL LINE
June 11, 2020
INNOVATION PHARMACEUTICALS COLLABORATING WITH REGIONAL BIOCONTAINMENT LAB ON GRANT APPLICATION TO RESEARCH BRILACIDIN AS A PAN-CORONAVIRUS THERAPEUTIC
May 26, 2020
INNOVATION PHARMACEUTICALS RECEIVES DATA FROM PUBLIC HEALTH RESEARCH INSTITUTE SHOWING BRILACIDIN INHIBITS SARS-COV-2 (COVID-19) IN A HUMAN CELL LINE
May 19, 2020
INNOVATION PHARMACEUTICALS’ BRILACIDIN REDUCES VIRAL TITER OF SARS-COV-2 (COVID-19) BY 75 PERCENT AFTER ONLY 1 HOUR OF PREINCUBATION IN IN VITRO STUDY AT BSL-3 FACILITY
May 5, 2020
INHIBITORY EFFECT OF INNOVATION PHARMACEUTICALS’ BRILACIDIN ON SARS-COV-2 (COVID-19) IN PRIMARY HUMAN IMMUNE CELLS TO BE STUDIED AT LEADING PUBLIC HEALTH RESEARCH INSTITUTE
April 27, 2020
INNOVATION PHARMACEUTICALS INFORMED NEXT PHASE OF BRILACIDIN CORONAVIRUS (COVID-19) TESTING TO BEGIN WEEK OF MAY 4
April 20, 2020
SCREENING OF 11,552 COMPOUNDS IDENTIFIES INNOVATION PHARMACEUTICALS’ BRILACIDIN AS ONE OF THE MOST PROMISING POTENTIAL INHIBITORS OF THE NOVEL CORONAVIRUS
April 6, 2020
INNOVATION PHARMACEUTICALS IN DISCUSSIONS TO ADVANCE BRILACIDIN INTO HUMAN TRIALS AGAINST COVID-19
April 1, 2020
INNOVATION PHARMACEUTICALS RECEIVES DATA SUPPORTING BRILACIDIN’S DIRECT INHIBITION OF SARS-COV-2, THE NOVEL CORONAVIRUS RESPONSIBLE FOR COVID-19
March 17, 2020
INNOVATION PHARMACEUTICALS BRILACIDIN TO BE RESEARCHED AS POSSIBLE NOVEL CORONAVIRUS (COVID-19) VACCINE; BRILACIDIN NOW BEING TESTED AS DRUG AND VACCINE AT DIFFERENT INSTITUTIONS
March 12, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES TESTING PROCEDURES OF BRILACIDIN AGAINST CORONAVIRUS (COVID-19)
March 10, 2020
U.S. REGIONAL BIOCONTAINMENT LAB TO BEGIN TESTING OF BRILACIDIN AGAINST CORONAVIRUS (COVID-19) NEXT WEEK
March 9, 2020
INNOVATION PHARMACEUTICALS BRILACIDIN RECEIVED BY U.S. REGIONAL BIOCONTAINMENT LABORATORY; TESTING AGAINST CORONAVIRUS (COVID-19)
March 6, 2020
INNOVATION PHARMACEUTICALS SIGNS SECOND MTA TO EXPLORE BRILACIDIN AS CORONAVIRUS COVID-19 TREATMENT
March 5, 2020
INNOVATION PHARMACEUTICALS PLANS FOR PHASE 2 TRIAL OF NEW TREATMENT FOR ULCERATIVE COLITIS
March 2, 2020
INNOVATION PHARMACEUTICALS PROVIDES SCIENTIFIC RATIONALE AND CLINICAL DEVELOPMENT PERSPECTIVES FOR BRILACIDIN AS A POTENTIAL NOVEL CORONAVIRUS COVID-19 TREATMENT
February 27, 2020
INNOVATION PHARMACEUTICALS TO SHIP BRILACIDIN TO U.S. REGIONAL BIOCONTAINMENT LABORATORY FOR RESEARCH AGAINST CORONAVIRUS COVID-19
February 24, 2020
INNOVATION PHARMACEUTICALS SUBMITS MATERIAL TRANSFER AGREEMENT TO STUDY LEAD DEFENSIN MIMETIC BRILACIDIN FOR CORONAVIRUS (COVID-19)
February 18, 2020
INNOVATION PHARMACEUTICALS EXPLORING LEAD DEFENSIN MIMETIC DRUG CANDIDATE BRILACIDIN AS POTENTIAL NOVEL CORONAVIRUS TREATMENT
February 13, 2020
INNOVATION PHARMACEUTICALS PHASE 1 TRIAL OF BRILACIDIN FOR ULCERATIVE COLITIS MEETS PRIMARY ENDPOINTS; POSITIVE TOPLINE RESULTS OF ORAL BRILACIDIN
January 29, 2020
INNOVATION PHARMACEUTICALS FURTHER ENGAGES LOCUST WALK TO LEAD OUT-LICENSING NEGOTIATIONS FOR RIGHTS TO PHASE 3-READY ORAL MUCOSITIS DRUG CANDIDATE
January 24, 2020
INNOVATION PHARMACEUTICALS COMPLETES DOSING IN PHASE 1 TRIAL FOR NEW ORAL ULCERATIVE COLITIS DRUG
January 17, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES DOSE ESCALATION
January 16, 2020
INNOVATION PHARMACEUTICALS ANNOUNCES DOSING OF FIRST COHORT IN PHASE 1 TRIAL OF ORAL BRILACIDIN IN ULCERATIVE COLITIS PROGRAM; TOPLINE RESULTS ANTICIPATED EARLY Q1 2020
December 26, 2019
INNOVATION PHARMACEUTICALS: PATIENT SCREENING FOR PHASE 1 TRIAL OF ORAL BRILACIDIN IN ULCERATIVE COLITIS PROGRAM ON TRACK FOR EARLY JANUARY
December 13, 2019
INNOVATION PHARMACEUTICALS GRANTED REGULATORY APPROVAL TO START PHASE 1 TRIAL OF ORAL BRILACIDIN IN ULCERATIVE COLITIS PROGRAM
December 10, 2019
INNOVATION PHARMACEUTICALS PROVIDES UPDATE ON CLINICAL TRIALS AND REVENUE POTENTIAL OF BRILACIDIN IN INFLAMMATORY BOWEL DISEASES
November 25, 2019
INNOVATION PHARMACEUTICALS AND FDA AGREE TO WAIVE INITIAL PEDIATRIC STUDY PLAN REQUIREMENT REGARDING BRILACIDIN FOR THE PREVENTION OF ORAL MUCOSITIS
November 13, 2019
INNOVATION PHARMACEUTICALS: ORAL CANCER ON THE RISE; COMPANY OFFERS PERSPECTIVES ON OPPORTUNITY OF BRILACIDIN FOR THE PREVENTION OF ORAL MUCOSITIS
October 28, 2019
INNOVATION PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA BY INDEPENDENT CANCER RESEARCHERS SUPPORTING P53 DRUG CANDIDATE KEVETRIN’S POTENTIAL IN TREATING ACUTE MYELOID LEUKEMIA
October 14, 2019
INNOVATION PHARMACEUTICALS PARTNERING PROVIDES MOMENTUM FOR INFLAMMATORY BOWEL DISEASE PROGRAMS, TARGETING A SUBSTANTIAL AND PRIZED MARKET WITH A LARGE UNMET PATIENT NEED
October 8, 2019
INNOVATION PHARMACEUTICALS CITES RECENT ACADEMIC LITERATURE SHOWING HOST DEFENSE PROTEINS AT CUTTING-EDGE OF MEDICINE FOR MULTIPLE DISEASES
(13)
(0)Scroll down for more posts ▼
